BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33452612)

  • 21. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Furan and p-xylene as candidate biomarkers for prostate cancer.
    Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
    Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.
    Principe S; Kim Y; Fontana S; Ignatchenko V; Nyalwidhe JO; Lance RS; Troyer DA; Alessandro R; Semmes OJ; Kislinger T; Drake RR; Medin JA
    J Proteome Res; 2012 Apr; 11(4):2386-96. PubMed ID: 22339264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomics in diagnosis of prostate cancer.
    Davalieva K; Polenakovic M
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):5-36. PubMed ID: 26076772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Update on the diagnosis of PCa in urine. The current role of urine markers].
    Fernandez-Serra A; Casanova-Salas I; Rubio L; Calatrava A; García-Flores M; García-Casado Z; López-Guerrero JA; Rubio-Briones J
    Arch Esp Urol; 2015 Apr; 68(3):240-9. PubMed ID: 25948797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
    Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
    Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
    Hendriks RJ; van Oort IM; Schalken JA
    Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
    Filella X; Foj L
    Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary RNA-based biomarkers for prostate cancer detection.
    Martignano F; Rossi L; Maugeri A; Gallà V; Conteduca V; De Giorgi U; Casadio V; Schepisi G
    Clin Chim Acta; 2017 Oct; 473():96-105. PubMed ID: 28807541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In silico verification and parallel reaction monitoring prevalidation of potential prostate cancer biomarkers.
    Adeola HA; Calder B; Soares NC; Kaestner L; Blackburn JM; Zerbini LF
    Future Oncol; 2016 Jan; 12(1):43-57. PubMed ID: 26615920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of candidate diagnostic and prognostic biomarkers for human prostate cancer: RPL22L1 and RPS21.
    Liang Z; Mou Q; Pan Z; Zhang Q; Gao G; Cao Y; Gao Z; Pan Z; Feng W
    Med Oncol; 2019 May; 36(6):56. PubMed ID: 31089825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
    Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
    Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
    Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
    J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic analysis of urinary extracellular vesicles from high Gleason score prostate cancer.
    Fujita K; Kume H; Matsuzaki K; Kawashima A; Ujike T; Nagahara A; Uemura M; Miyagawa Y; Tomonaga T; Nonomura N
    Sci Rep; 2017 Feb; 7():42961. PubMed ID: 28211531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary Biomarkers for Prostate Cancer.
    Giunchi F; Ciccarese C; Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L; Moch H; Massari F; Fiorentino M
    Curr Drug Metab; 2017 Oct; 18(8):723-726. PubMed ID: 28524004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice.
    Katafigioti A; Katafigiotis I; Sfoungaristos S; Alamanis C; Stravodimos K; Anastasiou I; Roumelioti E; Duvdevani M; Constantinides C
    Arch Ital Urol Androl; 2016 Oct; 88(3):195-200. PubMed ID: 27711093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.